People | October 07, 2022
Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
Roy is the right successor to lead Philips’ efforts to help improve the health and well-being of people globally
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
